On this week’s episode, Josh Schimmer,  Yaron Werber, Brian Skorney, Tess Cameron, and Eric Schmidt kick off the show covering the macro news of the week including the new FTC head and what it means for M&A in the industry. The group also discusses how the biopharma industry is not challenging RFK Jr., the BioSecure Act missing from the Defense Bill and Luigi Mangione’s arrest. In ASH Conference highlights, the hosts recap the CAR-T battle of Arcellx/Gilead vs Ligand/J&J, as well as updates from Agios and other SCD cell therapies. Other topics discussed include Blenrep’s return, BTK degraders from Beigene and Nurix, the Revance/Crown deal as well the big stock movers off the week. This episode aired on December 13, 2024.